ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 526,14
0,30%
Dow Jones
38 589,16
-0,15%
DAX
18 028,55
0,04%
Brent Oil
82,45
0,40%
Bitcoin
65 797,15
-1,26%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Keros Therapeutics Inc (KROS)

  7. Keros Therapeutics Inc (KROS) Actualités

KROS

Keros Therapeutics (KROS)

Keros Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KROS
DateHeureSourceTitreSymboleSociété
17/06/202412h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
17/06/202412h00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
04/06/202414h00GlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
03/06/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
03/06/202414h00GlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/05/202422h01GlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
14/05/202416h00GlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
08/05/202414h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
08/05/202414h00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
14/03/202413h00GlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
05/03/202414h00GlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/02/202422h01GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
29/01/202414h00GlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
09/01/202414h00GlobeNewswire Inc.Keros Therapeutics Announces Closing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
04/01/202422h04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KROSKeros Therapeutics Inc
04/01/202422h02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
04/01/202403h29GlobeNewswire Inc.Keros Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
03/01/202422h05GlobeNewswire Inc.Keros Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
11/12/202312h00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
07/11/202314h00GlobeNewswire Inc.Keros Therapeutics to Present at Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
06/11/202314h00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
02/11/202314h00GlobeNewswire Inc.Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
04/10/202314h00GlobeNewswire Inc.Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle SocietyNASDAQ:KROSKeros Therapeutics Inc
07/08/202314h00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
27/07/202322h01GlobeNewswire Inc.Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionNASDAQ:KROSKeros Therapeutics Inc
24/07/202314h00GlobeNewswire Inc.Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionNASDAQ:KROSKeros Therapeutics Inc
12/06/202323h33Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:KROSKeros Therapeutics Inc
12/06/202322h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
12/06/202314h00GlobeNewswire Inc.Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
09/06/202312h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
EU
AF
Air FranceKLM
EU
ORA
Orange
EU
BEL20
Bel 20
SPI
SP500
S&P 500
NASDAQ
MSFT
Microsoft
NYSE
DIS
Walt Disney
EU
HO
Thales
EU
VK
Vallourec
COIN
ETHUSD
Ethereum
EU
LR
Legrand
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés